Clinical Trial Update: Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This document notes the completion of a Phase 1 drug-drug interaction study of Ofatumumab with Bendamustine in indolent B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 1 | Status: COMPLETED